ocular involvement in behcet's disease. Behcet's disease
Conditions
Interventions
Intervention 1: Intervention group: Intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at the beginning of treatment. Intervention 2: Control group: 100cc D/w5%
Treatment - Drugs
Placebo
Intervention group: Intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at the beginning of treatment
Control group: 100cc D/w5% on 3 consecutive days at the beginning of treatment
Sponsors
Rheumatology Research Center
Eligibility
Sex/Gender
All
Age
10 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diagnosed Behcet's disease according to international criteria, New or relapse of retinal vasculitis who received any cytotoxic or glucocorticoid since 2 months ago, or new or relapse of severe posterior uveitis who are candidate for cyclophosphamide and azathioprine according to their physician Exclusion criteria: not Signing the informed consent, Visual acuity lower than 1/10 by Snellen chart, presence of infectious diseases such as TB, presence of diabetes mellitus, hypertension, heart disease, liver disease, renal disease, or edema, presence of other glucocorticoid consumption contraindications
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular IBDDAM INDEX. Timepoint: Before and 2 months after treatment. Method of measurement: ophthalmologist record.;Visual acuity. Timepoint: Before intervention and then every 2 months for 6 months. Method of measurement: ophthalmologist record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammation in retina. Timepoint: Before and two months after intervention. Method of measurement: ophthalmologist record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMastaneh Mohammadi
Tehran University of Medical Sciences and Health Services
Outcome results
None listed